Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis

Psoriasis is a chronic inflammatory skin disease that affects 2–3% of the global population, and there is still no known possibility of a cure. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. BML-111 (5(S)-6(R...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xinxin, Wang, Xin, Duan, Xiaoru, Poorun, Devesh, Xu, Juntao, Zhang, Song, Gan, Lu, He, Mengwen, Zhu, Ke, Ming, Zhangyin, Hu, Feng, Chen, Hongxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541073/
https://www.ncbi.nlm.nih.gov/pubmed/28769106
http://dx.doi.org/10.1038/s41598-017-07485-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541073/
https://www.ncbi.nlm.nih.gov/pubmed/28769106
http://dx.doi.org/10.1038/s41598-017-07485-1

Ejemplares similares